Provided by Tiger Trade Technology Pte. Ltd.

Graf Acquisition Corp. IV

8.35
0.0000
Volume:- -
Turnover:- -
Market Cap:86.62M
PE:1.24K
High:8.35
Open:8.35
Low:8.35
Close:8.35
52wk High:8.35
52wk Low:8.35
Shares:10.37M
Float Shares:8.56M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0067
EPS(LYR):0.2120
ROE:--
ROA:-2.46%
PB:-10.14
PE(LYR):39.38

Loading ...

Company Profile

Company Name:
Graf Acquisition Corp. IV
Exchange:
NYSE
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Website:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.